Pharmacologic treatments for covid-19 patients

Lopinavir + Ritonavir vs Umifenovir


Hospitalized patients

Forest plots
(last update: 2021-06-18)

Summary of findings
(last update: 2022-03-30)

To access all information :

You can print it as a pdf. You can also click on each forest plot with your right mouse button and download.

Permanent URL for this comparison: https://covid-nma.com/living_data/index.php?comparison=4

Back to your research

Trial Funding Comparisons Design Participants Sample size Overall risk
of bias
Highest assessment
Full description
Treatment 1 Treatment 2
IRCT20180725040596N2
Nojomi M, BMC Infect Dis., 2020
Full text
Commentary
Public/non profit

HCQ+LPV/r

HCQ+Umif

RCT Patients with COVID-19 (moderate-severe) admitted to a single center in Iran N=100
Some concerns
Details

Full description

NCT04252885
Yueping L, CellPress, 2020
Full text
Commentary
Public/non profit

Lopinavir-Ritonavir

Umifenovir

Lopinavir-Ritonavir

Standard care

Standard care

Umifenovir

RCT Patients with confirmed COVID-19 (mild-moderate) admitted to a single center in China. N=86
Some concerns
Details

Full description